Glycoprotein 96 and α-Fetoprotein Cross-Linking Complexes Elicited Specific Antitumor Immunity

Wang, Xiaoping; Wang, Qiaoxia; Lin, Huanping; Wang, Yali; Yang, Yixin

doi:10.1089/cbr.2012.1404

Cited by 9 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the findings further researches have also confirmed that conjugating HSP70 to AFP antigen could improve the potency of AFP fusion vaccines [ 49 , 50 , 63 – 68 ]. In recent years, we developed a series of potential therapeutic proteins or peptide vaccines HSP70-AFP, HSP70-AFP-P, and gp96-AFP-P; the recombinant vaccine can induce specific antitumor immunity against AFP-positive tumor cells [ 49 , 50 , 67 ]. Most of all, a novel therapeutic vaccine, HSP70-P/AFP-P, was constructed to enhance the immunogenicity of AFP by conjugating AFP epitope peptide with the HSP70 functional peptide via peptide synthesis.…”

Section: Application Of Afp In the Immunotherapy Of Hepatocellularmentioning

confidence: 99%

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Wang

2018

Canadian Journal of Gastroenterology and Hepatology

114

View full text Add to dashboard Cite

Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has become a target for liver cancer immunotherapy. Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer.

show abstract

Section: Application Of Afp In the Immunotherapy Of Hepatocellularmentioning

confidence: 99%

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Wang

2018

Canadian Journal of Gastroenterology and Hepatology

114

View full text Add to dashboard Cite

show abstract

“…A phase I clinical trial demonstrated that all six tested patients generated CD8-positive T-cell responses to the peptides as measured by direct IFN-γ enzyme-linked immunospot (ELIspot) and MHC class I tetramer assays[ 26 ]. Specific CD8-positive T cell response may be augmented by the use of AFP conjugated with heat shock protein (HSP)70[ 27 ], HSP72[ 27 ], or glycoprotein 96[ 28 ], as revealed by studies using mouse AFP-expressing tumors. Butterfield and colleagues further examined the efficacy of AFP-pulsed DC transfer and demonstrated that six out of the ten subjects generated significant AFP-positive T cell responses to the administered peptides, although nine showed progressive disease[ 26 ].…”

Section: Current and Emerging Immunotherapy Approachesmentioning

confidence: 99%

Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma

Mukaida¹,

Nakamoto²

2018

WJG

View full text Add to dashboard Cite

Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells (APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma (HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from non-cancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.

show abstract

“…The vaccines acted synergistically to significantly increase the AFP‐specific CD8 + T cell responses and produced an impressive cytotoxic antitumor effect against AFP‐expressing tumors. These data suggested that tumor vaccines by cross‐linking tumor antigen and heat shock protein 72 and glycoprotein 96 are promising approaches to cancer therapy . Diethylnitrosamine injected into infant mice resulted in the development of multinodular HCC in which AFP is expressed.…”

Section: Immunotherapeutic Strategiesmentioning

confidence: 99%

Promising new strategies for hepatocellular carcinoma

Nakamoto

2016

Hepatology Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer death worldwide. It usually arises based on a background of chronic liver diseases, defined as the hypercarcinogenic state. The current treatment options for HCC ranging from locoregional treatments to chemotherapies, including sorafenib, effectively regulate the limited sizes and numbers of the nodules. However, these treatments remain unsatisfactory because they have insufficient antitumor effects on the large and numerous nodules associated with HCC and because of a high recurrence rate in the surrounding inflamed liver. To develop novel and promising therapies with higher antitumor effects, recent progress in identifying molecular targets and developing immunological procedures for HCC are reviewed. The molecular targets discussed include the intracellular signaling pathways of protein kinase B/mammalian target of rapamycin and RAS/RAF/mitogen-activated protein kinase, Wnt/β-catenin and glutamine synthetase, insulin-like growth factor, signal transducer and activator of transcription 3, nuclear factor-κB and telomerase reverse transcriptase, and c-MET. Immunological studies have focused mainly on target identification, T cells, natural killer cells, dendritic cells, natural killer T cells, and vaccine development.

show abstract

Glycoprotein 96 and α-Fetoprotein Cross-Linking Complexes Elicited Specific Antitumor Immunity

Cited by 9 publications

References 36 publications

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma

Promising new strategies for hepatocellular carcinoma

Contact Info

Product

Resources

About